{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:55Z","timestamp":1791876955349,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016017","name":"Duke-NUS Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019579","name":"SingHealth Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtm.2025.101462","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T16:55:25Z","timestamp":1744304125000},"page":"101462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-123X","authenticated-orcid":false,"given":"King Pan","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela Su-fern","family":"Seng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2996-7229","authenticated-orcid":false,"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101462_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtm.2025.101462_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtm.2025.101462_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.101","article-title":"Rapid production of clinical-grade SARS-CoV-2 specific T cells","volume":"3","author":"Leung","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omtm.2025.101462_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/cid\/ciad233","article-title":"Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients","volume":"77","author":"Haidar","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101462_bib5","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/s41591-023-02480-8","article-title":"SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1\/2 trial","volume":"29","author":"Papadopoulou","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101462_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jcyt.2024.05.014","article-title":"A phase I\/II study of adoptive SARS-CoV-2-specific T cells in immunocompromised hosts with or at risk of severe COVID-19 infection","volume":"26","author":"Seng","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtm.2025.101462_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells","volume":"33","author":"Hendel","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101462_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101462_bib9","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/eji.202049107","article-title":"Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis","volume":"51","author":"Guo","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib10","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101462_bib11","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101462_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13905","article-title":"Characterization of the interplay between DNA repair and CRISPR\/Cas9-induced DNA lesions at an endogenous locus","volume":"8","author":"Bothmer","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101462_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm9106","article-title":"Precise CRISPR-Cas-mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells","volume":"8","author":"Tran","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2025.101462_bib14","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1038\/s41596-021-00626-x","article-title":"Defining genome-wide CRISPR-Cas genome-editing nuclease activity with GUIDE-seq","volume":"16","author":"Malinin","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2025.101462_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101462_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtm.2025.101462_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmj.p264","article-title":"Covid-19: FDA removes US authorisation for antibody drug Evusheld","volume":"380","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.omtm.2025.101462_bib18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtm.2025.101462_bib19","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/s41467-022-31485-z","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents","volume":"13","author":"Rosa Duque","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101462_bib20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/mt.2013.59","article-title":"HLA engineering of human pluripotent stem cells","volume":"21","author":"Riolobos","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101462_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101462_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12015-013-9457-0","article-title":"Generating hypoimmunogenic human embryonic stem cells by the disruption of beta 2-microglobulin","volume":"9","author":"Lu","year":"2013","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.omtm.2025.101462_bib23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted Disruption of the beta2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtm.2025.101462_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.omtm.2025.101462_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtm.2025.101462_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101462_bib27","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2025.101462_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1126\/science.1853205","article-title":"MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity","volume":"253","author":"Liao","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101462_bib29","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.4049\/jimmunol.138.6.1657","article-title":"NK susceptibility varies inversely with target cell class I HLA antigen expression","volume":"138","author":"Storkus","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215496","article-title":"Dimorphism of HLA-E and its Disease Association","volume":"20","author":"Kanevskiy","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101462_bib31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-13-1766","article-title":"Infusions of allogeneic natural killer cells as cancer therapy","volume":"20","author":"Leung","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtm.2025.101462_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2025.101462_bib33","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1038\/s41467-022-31543-6","article-title":"Massively targeted evaluation of therapeutic CRISPR off-targets in cells","volume":"13","author":"Pan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101462_bib34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101462_bib35","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtm.2025.101462_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.64","article-title":"COSMID: A Web-based Tool for Identifying and Validating CRISPR\/Cas Off-target Sites","volume":"3","author":"Cradick","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2025.101462_bib37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ymthe.2023.02.011","article-title":"Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34(+) hematopoietic stem and progenitor cells","volume":"31","author":"Cromer","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101462_bib38","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gky222","article-title":"Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption","volume":"46","author":"Gopalappa","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101462_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101462_bib40","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","article-title":"On- and off-target effects of paired CRISPR-Cas nickase in primary human cells","volume":"32","author":"Klermund","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101462_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101462_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101462_bib44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142167","article-title":"High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19","volume":"5","author":"Schub","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101462_bib46","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101462_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtm.2025.101462_bib48","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3324\/haematol.2018.207548","article-title":"Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease","volume":"104","author":"Kazi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2025.101462_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2017.10.004","article-title":"Virus-Specific T Cells: Broadening Applicability","volume":"24","author":"Barrett","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2025.101462_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101462_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2025.101462_bib52","article-title":"Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19","volume":"11","author":"Cooper","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.620730","article-title":"SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy","volume":"9","author":"Ferreras","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtm.2025.101462_bib54","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood.2020008488","article-title":"SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein","volume":"136","author":"Keller","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101462_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751869","article-title":"Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101462_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010339","article-title":"SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants","volume":"18","author":"Panikkar","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtm.2025.101462_bib57","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.3324\/haematol.2022.281946","article-title":"Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients","volume":"108","author":"Vasileiou","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.omtm.2025.101462_bib58","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood.2020005185","article-title":"Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR\/Cas9-mediated TCR knockout CAR","volume":"136","author":"Stenger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2025.101462_bib59","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1002\/acg2.45","article-title":"Allogeneic CD 27-depleted cells in adoptive cell therapy","volume":"2","author":"Talleur","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omtm.2025.101462_bib60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/leu.2014.174","article-title":"Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity","volume":"29","author":"Chan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2025.101462_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/crispr.2020.0141","article-title":"Universal Gene Correction Approaches for beta-hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates","volume":"4","author":"Lamsfus-Calle","year":"2021","journal-title":"CRISPR J."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:50:11Z","timestamp":1759863011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2329050125000579"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101462","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101462"}}